Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.67 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.57 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.57 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.57 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | TK2 | O00142 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29495147 | 0.86 | PYGM (0.67) | PYGMP2RY6P2RY2DNPH1P2RY14 | |
| SCHEMBL5315376 | 0.86 | DNPH1 (0.51) | PYGMP2RY6P2RY2DNPH1P2RY14 | |
| SCHEMBL7152594 | 0.86 | PYGM (0.86) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL27778954 | 0.84 | P2RY6 (0.48) | PYGMP2RY6DNPH1P2RY14NT5E | |
| SCHEMBL6839685 | 0.83 | PYGM (0.81) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL28372181 | 0.82 | DNPH1 (0.74) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL3469958 | 0.82 | DNPH1 (0.74) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL3084985 | 0.82 | PYGM (0.67) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL9796913 | 0.82 | DNPH1 (0.74) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL6758925 | 0.82 | PYGM (0.97) | PYGMP2RY6P2RY2P2RY4DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166896-A1 | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | disclosed |
| US-6528639-B2 | Active ribozyme | RIBOZYME PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | disclosed |
| US-20010006801-A1 | BASE-MODIFIED ENZYMATIC NUCLEIC ACID | USMAN NASSIM (US) | 2001-07-05 | — | — | US | disclosed |
| US-5891684-A | RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5879938-A | RIBOZYME WITH INCREASED ACTIVITY BY SUBSTITUTION OF MODIFIED NUCLEOTIDE INTO SUBSTRATE BINDING ARM OR CATALYTIC CORE | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-03-09 | — | — | US | disclosed |
| US-5767263-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0799313-A2 | METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5672511-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| US-5672501-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| EP-0728204-A1 | BASE-MODIFIED ENZYMATIC NUCLEIC ACID | RIBOZYME PHARMACEUTICALS, INC. (US) | 1996-08-28 | — | — | EP | disclosed |
| WO-1996018736-A2 | METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1996-06-20 | — | — | WO | disclosed |
| WO-1995013378-A1 | BASE-MODIFIED ENZYMATIC NUCLEIC ACID | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166896-A1 | Base-modified enzymatic nucleic acid | RNASE1, RNGTT, RNASEL | PYGM 1431/4885P2RY6 3658/4885P2RY2 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.